U.S. Patent 9,707,191: Scope, Claims, and Landscape Analysis
Executive Summary
U.S. Patent 9,707,191, granted on July 18, 2017, to Bristol-Myers Squibb Company, covers methods of treating certain cancers. The patent focuses on the co-administration of a programmed cell death protein 1 (PD-1) inhibitor with a Janus kinase (JAK) inhibitor. The claims define specific dosing regimens and patient populations. The patent landscape reveals a complex interplay of intellectual property surrounding PD-1 inhibition, with significant activity from major pharmaceutical companies.
What Does U.S. Patent 9,707,191 Claim?
What is the core invention described in U.S. Patent 9,707,191?
The patent describes methods for treating hyperproliferative disorders, specifically cancers. The core invention is the co-administration of a PD-1 inhibitor with a JAK inhibitor to achieve a therapeutic effect.
What specific conditions are covered by the patent's claims?
The patent claims cover the treatment of hyperproliferative disorders, including but not limited to:
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Renal cell carcinoma (RCC)
- Bladder cancer
- Head and neck cancer
- Gastric cancer
- Colorectal cancer
What are the key components of the claimed treatment regimen?
The claimed treatment regimen involves the co-administration of:
- A PD-1 inhibitor: This is a compound that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated immunity. Examples of PD-1 inhibitors referenced in the patent include nivolumab and pembrolizumab.
- A JAK inhibitor: This is a compound that inhibits one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2). These enzymes are involved in intracellular signaling pathways that regulate cell growth, differentiation, and immune responses. Examples of JAK inhibitors mentioned in the patent include tofacitinib.
What are the specific dosage and administration parameters defined in the claims?
The claims specify particular dosing parameters for both the PD-1 inhibitor and the JAK inhibitor. For instance, claim 1 details administering a PD-1 inhibitor and a JAK inhibitor in a manner that results in a decrease in the size of a tumor. Specific dosages are not universally prescribed across all claims but are often linked to achieving a therapeutic outcome. The patent emphasizes the combination therapy approach.
What are the limitations or exclusions within the claims?
The claims are primarily focused on the method of treatment and the combination of specific drug classes. While specific drug examples are provided, the claims are generally broad enough to cover any PD-1 inhibitor and any JAK inhibitor when used in the described therapeutic context. The claims do not, for example, define novel compounds themselves but rather novel uses of known or discoverable compounds.
What is the Patent Landscape for U.S. Patent 9,707,191?
Who are the key patent holders in the PD-1 inhibitor space?
The PD-1 inhibitor space is dominated by a few key players, including:
- Bristol-Myers Squibb Company: Holder of U.S. Patent 9,707,191, and innovator of nivolumab (Opdivo).
- Merck & Co., Inc.: Holder of key patents related to pembrolizumab (Keytruda).
- AstraZeneca PLC: Holds patents related to durvalumab (Imfinzi).
- Roche Holding AG: Holds patents related to atezolizumab (Tecentriq).
How does U.S. Patent 9,707,191 fit within the broader immunotherapy patent landscape?
U.S. Patent 9,707,191 represents a strategic extension of the PD-1 inhibitor intellectual property portfolio. It moves beyond the patenting of the individual PD-1 inhibitor compounds to encompass combination therapies. This approach aims to broaden market exclusivity by protecting novel treatment regimens that enhance efficacy or address resistance mechanisms.
Are there pending patent applications related to PD-1/JAK inhibitor combinations?
Yes, the patent landscape shows ongoing innovation in combination therapies involving PD-1 inhibitors. Numerous patent applications are filed by various pharmaceutical companies exploring different combinations of immunotherapies, including PD-1 inhibitors with other agents like chemotherapy, targeted therapies, and other immunomodulatory drugs, including JAK inhibitors. The specific focus on JAK inhibitors as a co-administered agent in conjunction with PD-1 blockade is a notable area of patenting activity.
What is the competitive intelligence regarding other JAK inhibitor combination patents?
The use of JAK inhibitors in combination with other cancer therapies, including immunotherapies, is an active area of patent prosecution. Competitors are exploring various JAK family members and specific JAK inhibitors, often claiming particular cancer types, patient stratification methods, or specific dosing schedules. This indicates a competitive race to secure intellectual property for novel combination strategies that aim to improve patient outcomes in oncology.
What are the implications of this patent for biosimilar and generic drug development?
For biosimilar developers targeting PD-1 inhibitors, U.S. Patent 9,707,191 poses a challenge. While a biosimilar might seek to replicate the efficacy of the original PD-1 inhibitor compound, it would need to navigate any patents covering specific methods of use or combination therapies involving that compound. The granted patent on a specific combination method means that generic or biosimilar versions of the PD-1 inhibitor may be restricted from being marketed for the specific therapeutic uses claimed by this patent, even after the compound patent expires. This necessitates careful analysis of the remaining term and scope of method-of-use patents.
What is the Patent Validity and Enforcement Landscape?
What is the term of U.S. Patent 9,707,191?
U.S. Patent 9,707,191 was granted on July 18, 2017. Under standard U.S. patent law, patents typically last 20 years from the filing date. The original filing date for this patent was October 16, 2015. Therefore, the patent is expected to expire in October 2035. However, patent term adjustments (PTA) or extensions (PTE) due to regulatory review could potentially extend this term.
What are the potential challenges to the validity of this patent?
Potential challenges to patent validity can arise from:
- Prior art: Arguments that the claimed invention was already known or obvious at the time of filing. This could include prior scientific publications, existing patents, or public disclosures.
- Enablement and written description: Claims that the patent does not adequately describe or enable the claimed invention for someone skilled in the art.
- Obviousness-type double patenting: If claims in this patent are found to be patentably indistinct from claims in other patents owned by the same assignee with overlapping terms.
How has Bristol-Myers Squibb enforced its PD-1 inhibitor patents previously?
Bristol-Myers Squibb has a history of vigorously enforcing its intellectual property related to PD-1 inhibitors, particularly for nivolumab. This has involved litigation against competitors seeking to launch biosimilar or generic versions of the drug, as well as defending against challenges to its core patents. Enforcement actions often focus on protecting market exclusivity for both the drug substance and its approved methods of use.
What is the typical patent litigation strategy for method-of-use patents like this one?
Litigation strategy for method-of-use patents typically centers on demonstrating infringement. This involves proving that a competitor's product is being marketed or used for the specific patented method. Defenses by alleged infringers often include non-infringement arguments (e.g., their product is not used for the patented method) or challenging the patent's validity. The scope of the claims, particularly the definition of the "method," "co-administration," and the specific therapeutic outcomes, becomes critical in infringement analysis.
What is the potential impact of Hatch-Waxman Act provisions on this patent?
The Hatch-Waxman Act provides a framework for the approval of generic drugs and abbreviated new drug applications (ANDA). While the primary focus is on the active pharmaceutical ingredient (API), the Act also allows for the listing of method-of-use patents in the Orange Book. If this patent is listed, generic applicants must certify that their proposed product does not infringe the patent, or that the patent is invalid. This can lead to patent dance negotiations and potential litigation. For biosimil, the Biologics Price Competition and Innovation Act (BPCIA) has a similar, though distinct, patent dispute resolution process.
Key Takeaways
U.S. Patent 9,707,191 provides Bristol-Myers Squibb with a crucial layer of intellectual property protection for a specific combination therapy involving PD-1 inhibitors and JAK inhibitors for cancer treatment. The patent's expiration in October 2035, barring any adjustments, offers extended market exclusivity for this particular method of use. The patent landscape indicates significant ongoing research and patenting activity in combination immunotherapies, highlighting a competitive environment where strategic patenting of novel treatment regimens is paramount. Companies seeking to enter the PD-1 inhibitor market, whether through generic or biosimilar pathways, must carefully assess the scope and remaining term of method-of-use patents like U.S. Patent 9,707,191 to avoid infringement and potential litigation.
Frequently Asked Questions
What is the primary therapeutic target of the PD-1 inhibitor described in the patent?
The primary therapeutic target is the programmed cell death protein 1 (PD-1) receptor on T-cells, blocking its interaction with ligands PD-L1 and PD-L2. This blockade restores T-cell activity against cancer cells.
Can this patent be infringed by a generic PD-1 inhibitor used alone?
No, this patent specifically claims the co-administration of a PD-1 inhibitor with a JAK inhibitor. Using a generic PD-1 inhibitor alone, for a condition not covered by this specific method claim, would not directly infringe this patent. Infringement would occur if the generic PD-1 inhibitor were used in conjunction with a JAK inhibitor as described in the patent claims.
What is the significance of the JAK inhibitor component in this patent?
The JAK inhibitor component is significant as it represents a synergistic or additive effect when combined with a PD-1 inhibitor. This combination aims to enhance anti-tumor efficacy, potentially by modulating the tumor microenvironment, reducing immunosuppression, or overcoming resistance mechanisms to PD-1 blockade alone.
Does this patent cover the synthesis or manufacturing process of PD-1 or JAK inhibitors?
No, U.S. Patent 9,707,191 is a method-of-use patent. It does not cover the synthesis, manufacturing process, or composition of matter for the individual PD-1 or JAK inhibitor compounds themselves. These aspects would be protected by separate patents.
How might a company circumvent this patent if they wish to develop a similar combination therapy?
Circumvention strategies could involve developing a combination therapy using different classes of drugs that achieve a similar therapeutic outcome but do not fall within the specific claim language of U.S. Patent 9,707,191. Alternatively, one could develop a treatment regimen with significantly different dosing, administration schedules, or target patient populations that are not encompassed by the patent's claims. Invalidating the patent through legal challenges is another potential, albeit costly, avenue.
Citations
[1] Bristol-Myers Squibb Company. (2017). U.S. Patent 9,707,191: Methods of treating hyperproliferative disorders. United States Patent and Trademark Office. (Original filing date: October 16, 2015; Grant date: July 18, 2017).
